Research Article | Open Access
Guolei Dong, Xiaorui Wang, Yan Jia, Yongsheng Jia, Weipeng Zhao, Jin Zhang, Zhongsheng Tong, "HAND2-AS1 Works as a ceRNA of miR-3118 to Suppress Proliferation and Migration in Breast Cancer by Upregulating PHLPP2", BioMed Research International, vol. 2020, Article ID 8124570, 16 pages, 2020. https://doi.org/10.1155/2020/8124570
HAND2-AS1 Works as a ceRNA of miR-3118 to Suppress Proliferation and Migration in Breast Cancer by Upregulating PHLPP2
Large quantities of long noncoding RNAs (lncRNAs) have been verified to exert vital functions in the process of breast cancer (BC). lncRNA heart and neural crest derivatives expressed 2-antisense RNA 1 (HAND2-AS1) was reported to suppress the development of several cancers. However, its detailed function in BC remained unclear. In the current study, HAND2-AS1 was discovered to be low expressed in BC cell lines, and overexpression of HAND2-AS1 could repress proliferation, migration, and invasion but facilitate apoptosis in BC cells. Moreover, HAND2-AS1 was found to act as a sponge of miR-3118 which was detected to be upregulated in BC cell lines. miR-3118 depletion could constrict the progression of BC. HAND-AS1 hindered the course of BC by reducing the expression of miR-3118. Besides, PHLPP2 was treated as a downstream target of miR-3118 under the selection of RNA pull-down assays. HAND2-AS1 inhibited the process of BC by enhancing expression of PHLPP2. In summary, our study testified that HAND2-AS1 suppressed BC growth by targeting the miR-3118/PHLPP2 axis, indicating that HAND2-AS1 could be regarded as a potential target for BC treatment.
Breast cancer (BC) is a common cancer with high morbidity among females globally . It was a great threat to female health and brought much trouble and disturbance to work and life. Great efforts were spared, and progress was achieved in treatment of BC . It is extremely crucial to make an early prognosis for BC. Thus, it is necessary to have a thorough understanding of the molecular mechanism of BC.
Substantial long noncoding RNAs (lncRNAs) were reported to bring about vital effects on the progression of cancers [3, 4]. UCA1 strengthened resistance to tamoxifen in BC via activating the Pl3K/AKT signaling pathway . FAGF13-AS1 was discovered to exert inhibitory effect on glycolysis and stemness in BC . lncRNA heart and neural crest derivatives expressed 2-antisense RNA 1 (HAND2-AS1) was introduced to be downregulated in colorectal cancer , chronic myeloid leukemia , and non-small-cell lung cancer . Nevertheless, its role has not been analyzed in BC.
Numerous essays acclaimed that the competing endogenous RNA (ceRNA) regulatory system played huge roles in regulating the mechanism of cancers [10, 11]. In this system, lncRNAs functioned as sponges of microRNAs (miRNAs), and their downstream target mRNAs were released to code into proteins [12, 13]. NEAT1 was identified as an oncogene in BC by targeting miR-448/ZEB1 . LINC01116 is competitively bound to miR-145 to regulate the expression of ESR1 in BC . In this study, we mainly studied the role of HAND2-AS1 in the ceRNA system.
miRNAs were a class of RNAs which were around 18-22 nucleotides in length without the capacity of coding proteins . Emerging studies indicated that aberrant expression of miRNAs acted as oncogene or tumor inhibitors in cancers. miR-590-5p was reported as a tumor inhibitor in BC by interacting with SOX2 . miR-198 exerted inhibitory effect on BC progression via targeting CUB . Nonetheless, how miR-3188 took part in the BC progression remained unclear.
The main purpose of our current study was to explore the role of HAND2-AS1 in BC cells.
2.1. Overexpression of HAND2-AS1 Repressed Proliferation, Migration, and Invasion in BC Cell
To investigate the role of HAND2-AS1 in BC, we used RT-qPCR assays to determine the expression of HAND2-AS1 in BC cell lines (MCF-7, MDA-MB-231, SK-BR-3, and MDA-MB-453) and normal mammary epithelial cell (MCF-10A). The results showcased that HAND2-AS1 was at a low level of expression in BC cell lines in comparison with MCF-10A (Figure 1(a)). Then, pcDNA3.1/HAND2-AS1 was transfected into MCF-7 and SK-BR-3 cells. The outcomes disclosed that HAND2-AS1 expression was rose dramatically in comparison with the normal control (Figure 1(b)). To explore the influence of HAND2-AS1 on the development of BC, we conducted gain-of-function assays. The ability of proliferation assessed by CCK8 and colony formation assays was attenuated via overexpression of HAND2-AS1 (Figures 1(c) and 1(d)). The apoptosis rate was ascended by overexpression of HAND2-AS1 (Figure 1(e)). The capacities of migration and invasion were lessened by pcDNA3.1/HAND2-AS1 in transwell assays (Figures 1(f) and 1(g)). The proteins of the epithelial-mesenchymal transition (EMT) process were examined by western blot. The consequences depicted that E-cadherin protein was enhanced but N-cadherin, MMP2, Vimentin, and slug proteins were declined by overexpression of HAND2-AS1 (Figure 1(h)). In brief, HAND2-AS1 was low expressed in BC cell lines and overexpression of HAND2-AS1 inhibited the process of BC.
2.2. miR-3118 Depletion Inhibited BC Proliferation While Facilitating Apoptosis in BC
To analyze the role of HAND2-AS1 in the ceRNA regulatory system, we performed FISH assays, and the outcomes displayed that HAND2-AS1 accumulated in cytoplasm (Figure 2(a)). Subsequently, with the help of starBase, we discovered several miRNAs with binding sites for HAND2-AS1. These miRNA expressions were evaluated in cells transfected with pcDNA3.1/HAND2-AS1. The results disclosed that only miR-3118 expression was decreased distinctly in contrast with the control group (Figure 2(b)). The binding sequences were exhibited by bioinformatics (Figure 2(c)). RNA pull-down assays were carried out, and the outcomes delineated that miR-3118-WT with biotinylation could make HAND2-AS1 abundant but miR-3118-Mut with biotinylation could not (Figure 2(d)). We tested the expression of miR-3118 increased prominently by miR-3118 mimics in comparison with the control group (Figure 2(e)). The activity of plasmid built with HAND2-AS1-WT was declined remarkably by miR-3118 mimics, but there were no evident changes in that set with HAND2-AS1-Mut (Figure 2(f)). miR-3118 expression was appraised in BC cell lines, and it was showed that miR-3118 expression was extremely high in BC cell lines (Figure 2(g)). The expression of miR-3118 was found to be diminished in cells transfected with miR-3118 inhibitor (Figure 2(h)). Afterwards, we explored the effect of miR-3118 on the BC progression. miR-3118 inhibitor was transfected into cells. The results showcased that miR-3118 depletion could inhibit proliferation (Figures 2(i) and 2(j)) but foster the apoptosis rate (Figure 2(k)). And the capacity of migration and invasion was weakened by miR-3118 inhibitor and so did the EMT process (Figures 2(l)–2(n)). In short, miR-3118 was a target of HAND2-AS1, and depletion of miR-3118 could inhibit the process of BC.
2.3. HAND2-AS1 Restricted the Process of BC by Inhibiting miR-3118
To find out how HAND2-AS1 regulated miR-3118 in BC, we conducted rescue assays. MCF-7 and SK-BR-3 cells were transfected with pcDNA3.1/HAND2-AS1 and miR-3188 mimics. The cell proliferation assessed by CCK8 and colony formation assays was declined by pcDNA3.1/HAND2-AS1, but miR-3118 mimics could rescue the results induced by HAND2-AS1 overexpression (Figures 3(a) and 3(b)). The increased rate of apoptosis induced by HAND2-AS1 overexpression could be rescued by miR-3118 mimics (Figure 3(c)). The lessened migration and invasion abilities assessed by transwell assays were counteracted by miR-3118 mimics (Figures 3(d) and 3(e)). Overexpression of HAND2-AS1 lifted the proteins of E-cadherin but decreased proteins of N-cadherin, MMP2, Vimentin, and slug, but miR-3118 mimics reversed the results made by HAND2-AS1 (Figure 3(f)). In conclusion, HAND2-AS1 inhibited the process of BC by downregulating miR-3118.
2.4. PHLPP2 Was a Downstream Target of miR-3118
Then, we searched the starBase and found that several mRNAs had possibilities to bind to miR-3118. RNA pull-down assays were applied, and the results manifested that biotinylated miR-3118-WT only could make PHLPP2 abundant while no changes could be seen in other mRNAs (Figure 4(a)). The binding sites between miR-3118 and PHLPP2 were predicted by bioinformatics (Figure 4(b)). miR-3118 inhibitor was transfected into cells, and the expression of PHLPP2 and proteins were measured by RT-qPCR and western blot. The results depicted that both PHLPP2 expression and proteins were increased by miR-3118 inhibitor (Figure 4(c)). RIP assays were applied, and the results revealed that HAND2-AS1, PHLPP2, and miR-3118 were enriched in Ago2 antibody not in IgG antibody (Figure 4(d)). Luciferase reporter assays were conducted, and the results showed that miR-3118 mimics diminished the activity of plasmid constructed with PHLPP2-WT but not that set with PHLPP2-Mut. After transfecting pcDNA3.1/HAND2-AS1 into cells, the activity of plasmid built with PHLPP2-WT was recovered partially (Figure 4(e)). In a word, PHLPP2 was a downstream target of miR-3118.
2.5. HAND2-AS1 Hindered the Course of BC through Elevating PHLPP2 Expression
To investigate how HAND2-AS1 mediated PHLPP2 in BC, we constructed rescue assays. Firstly, we examined the expression of HAND2-AS1 in cells transfected with sh-PHLPP2. The results revealed that PHLPP2 expression was cut down by sh-PHLPPP2 (Figure 5(a)). Then, pcDNA3.1/HAND2-AS1 and sh-PHLPP2 were transfected into cells. The results delineated that knockdown of PHLPP2 could rescue the effects of HAND2-AS1 overexpression on proliferation, apoptosis, migration, and invasion (Figures 5(b)–5(f)). The tendencies of relevant proteins induced by HAND2-AS1 overexpression in the EMT process were reversed by knockdown of PHLPP2 as well (Figure 5(g)). In summary, HAND2-AS1 could inhibit the progression of BC by stimulating the degradation of PHLPP2.
2.6. Overexpression of HAND2-AS1 Constricted the Growth of BC In Vivo
The effects of HAND2-AS1 on BC growth were verified in vivo. MCF-7 cells were transfected into pcDNA3.1/HAND2-AS1 and pcDNA3.1 vector. And the cells were injected into nude mice. After culture for 28 days, the process of tumor growth was recorded. The tumors transfected with pcDNA3.1/HAND2-AS1 grew slower than that with pcDNA3.1 vector (Figure 6(a)). The tumors were taken out, and both volume and weight of tumors with pcDNA3.1/HAND2-AS1 were smaller than that with pcDNA3.1 vector (Figures 6(b) and 6(c)). Immunohistochemistry was conducted to examine the expression of Ki67. The results revealed that Ki67 expression was declined conspicuously by pcDNA3.1/HAND2-AS1 compared with the normal control (Figure 6(d)). Collectively, overexpression of HAND2-AS1 could repress tumor growth in vivo.
In this study, we mainly analyzed HAND2-AS1 and discovered that it is downregulated in BC cell lines, which was in accordance with previous reports [19, 20]. In addition, HAND2-AS1 could suppress proliferation, migration, and invasion but accelerated death in BC cells, which was consistent with the findings in the previous study about the HAND2-AS1 role in cancers [20, 21]. In addition, there has not been research involving the effect of HAND2-AS1 in a breast cancer animal model. Therefore, we conducted experiments in vivo to disclose the influence of HAND2-AS1 upregulation on the progression of BC malignancy. The tumor volume in the mouse group with pcDNA3.1/HAND2-AS1 was smaller than that in the normal group. So was the tumor weight, supporting that HAND2-AS1 works as an inhibitor in breast cancer.
Previous studies demonstrated that lncRNAs sponged miRNAs to regulate mRNA expression and thus the progression of cancers in the ceRNA regulatory system [22, 23]. Specifically, HAND2-AS1 was reported to sponge miR-340-5p to upregulate BCL2L11, inducing cell apoptosis in BC . In this research, we discovered HAND2-AS1 targeted and inhibited miR-3118 in BC cell lines. Also, miR-3118 depletion repressed proliferative, invasive, and migratory capacities and promoted apoptosis of BC cells. The rescue assays demonstrated that HAND2-AS1 could hinder the process of BC by suppressing miR-3118 expression.
PHLPP2 was unveiled as a tumor suppressor in multiple cancers acting as an inhibitor of AKT and inducing apoptosis of cancer cells [25, 26]. On the other hand, microRNAs, lncRNAs, or other exogenous molecules interact with PHLPP2, thus modulating the cellular functions through the AKT pathway in tumors and diseases [27–30]. In our study, we selected out PHLPP2 by RNA pull-down assays from several mRNAs targeting miR-3118. Then, we knocked down the PHLPP2 in BC cells and discovered that inhibition of PHLPP2 greatly reversed the inhibitory impact on cell functions brought by HAND2-AS1. Taken together, this study showed that HAND2-AS1 sponges and inhibits miR-3118, curbing cell proliferation, migration, and invasion and inducing apoptosis of BC cells. Besides, miR-3118 suppressed PHLPP2 by targeting it while silencing PHLPP2 could alleviate the impact of HAND2-AS1 in BC. Therefore, we presented that HAND2-AS1 competed binding to miR-3188 with PHLPP2 and curbed the progression of breast cancer in vitro by elevating PHLPP2. In addition, in vivo assays also verified the suppressive effect of HAND2-AS1 in BC. However, there is one shortcoming in this present study. The subcutaneous tumor models are not sufficient for understanding of pathogenesis of breast cancer. Therefore, further tumor models are required to validate the role of HAND2-AS1 in the progression of breast cancer.
To sum up, our studies confirmed that HAND2-AS1 could inhibit BC proliferation, migration, and invasion and induce apoptosis as a ceRNA of miR-3188 to elevate PHLPP2 expression, which poses a potential that HAND2-AS1/miR-3188/PHLPP2 might be a therapeutic axis for breast cancer in the future.
4. Materials and Methods
4.1. Cell Lines and Transfection
BC cell lines (MDA-MB-231, MCF-7, SK-BR-3, and MDA-MB-453) and human mammary epithelial cell line (MCF10A) were both procured from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). DMEM, 10% fetal bovine serum (FBS), and 100 U/L penicillin/streptomycin were bought from Gibco (Grand Island, NY, USA) for cell culture in 5% CO2 at 37°C. MCF-7 and SK-BR-3 cells in 6-well plates ( cells/well) were prepared for 48 h of transfection utilizing Lipofectamine 2000 to differentiate the expression levels of HAND2-AS1, miR-3118, and PHLPP2 in cells (Invitrogen, Carlsbad, CA, USA). The overexpression plasmids pcDNA3.1/HAND2-AS1 and control (pcDNA3.1), miR-3118 mimics and NC mimics, as well as the silencing plasmids miR-3118 inhibitor and NC inhibitor, and sh-PHLPP2 and control (sh-NC) were all processed by RiboBio (Guangzhou, China).
4.2. Real-Time qPCR (RT-qPCR)
Total cellular RNAs were extracted from cell samples via the TRIzol reagent (Invitrogen) to synthesize cDNA with the PrimeScript RT reagent kit (Takara Biotechnology, Tokyo, Japan). qPCR was developed using SYBR Green PCR Master Mix (Invitrogen) on a Bio-Rad IQ5 thermocycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). RNA levels of HAND2-AS1, miR-3118, and PHLPP2 in all groups were normalized to U6 or GAPDH using the 2-ΔΔCT method.
4.3. Cell Counting Kit-8 (CCK8)
BC cells in 96-well plates ( cells/well) were incubated with CCK8 solution (Beyotime, Shanghai, China) in a 37°C, 5% CO2 incubator for 48 h. Cell viability in different groups was monitored by assessing the optical density by a microplate reader at absorbance of 450 nm.
4.4. Colony Formation Assay
Clonogenic cells of MCF-7 and SK-BR-3 were incubated in 6-well plates ( cells/well), following 14 days of incubation. Cells were stained with 0.5% crystal violet in 4% paraformaldehyde, and colonies were counted in all groups as a reference to the cell proliferation capability.
4.5. Cell Apoptosis Assay
BC cells were first washed in cold phosphate-buffered saline (PBS). Then, they were resuspended in 100 mL of binding buffer. 5 mL of Annexin V-FITC (Invitrogen) was added for 15 min in the dark at room temperature. Then, 5 mL of propidium iodide (PI; Invitrogen) was added for 15 min, followed by analysis of flow cytometry (BD Biosciences, San Jose, CA, USA). The flow cytometry assays analyzed changes in apoptosis rates in all groups.
4.6. Transwell Assay
Transfected BC cells were collected and incubated in serum-free medium. The 24-well transwell chamber (Costar, MA, USA) with matrigel coating was for invasion or migration assay. BC cells were put into the upper compartment, while the lower compartment was filled with complete culture medium. After 48 h of incubation, invasive and migratory cells were fixed and stained with 4% paraformaldehyde and 0.1% crystal violet for counting. The number of invaded or migrated cells was counted and served as a reference to cell migration or invasion ability in different groups.
4.7. Western Blotting
The western blotting method was used to observe the relative protein expression in cells of all groups. Protein samples from MCF-7 and SK-BR-3 cells were separated by electrophoresis on 10% SDS polyacrylamide gels and transferred onto PVDF membranes which were then blocked with 5% skimmed milk at room temperature for 2 h. The incubation with primary antibodies against E-cadherin, N-cadherin, MMP2, Vimentin, slug, PHLPP2, and GAPDH, along with the corresponding secondary antibodies (all from Abcam, Cambridge, MA, USA), was performed prior to analysis of the enhanced chemiluminescence reagent (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
4.8. FISH Assay
To investigate the localization of HAND1-AS1 in cells, we resorted to the FISH method. For the FISH assay, the HAND2-AS1 RNA probe was produced by RiboBio. After treating MCF-7 and SK-BR-3 cells with Hoechst, stained cells were photographed by a laser scanning confocal microscope (ZEISS, Jena, Germany).
4.9. RNA Pull-Down Assay
To investigate the interactions between RNAs involved, we performed RNA pull-down assay. The miR-3118-WT, miR-3118-Mut, and NC were biotin-labeled to Bio-miR-3118-WT, Bio-miR-3118-Mut, and Bio-NC by RiboBio, then incubated with cell lysates and Dyna-beads (Invitrogen). After washing, the bound RNAs were assayed by RT-qPCR.
4.10. Bioinformatics Analysis and Dual-Luciferase Reporter Assays
StarBase (http://starbase.sysu.edu.cn/agoClipRNA.php?source=lncRNA) was used online to predict the binding sites between HAND2-AS1 and miR-3118 as well as miR-3118 and PHLPP2. To confirm the bindings between HAND2-AS1 and miR-3118, and miR-3118 and PHLPP2, we did the dual-luciferase reporter assays. The pmirGLO Vector (Promega, Madison, WI, USA) containing the wild-type (WT) and mutant (Mut) miR-3118 binding sites within HAND2-AS1 sequence or PHLPP2 3-UTR were designed and termed as HAND2-AS1-WT/Mut and PHLPP2 WT/Mut. The indicated transfection plasmids were cotransfected into BC cells with HAND2-AS1-WT/Mut or PHLPP2 WT/Mut for 48 h, then examined by the Dual-Luciferase Assay System (Promega).
4.11. RNA Immunoprecipitation (RIP)
In light of the guidebook of Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore, Bedford, MA, USA), BC cells in RIP lysis buffer were subjected to immunoprecipitation with antibodies against Ago2 or control IgG (Millipore). After adding beads, the precipitates were assayed by RT-qPCR. The RIP method was used to assess the RNA enrichment in cells.
4.12. In Vivo Assay
6 weeks old of male nude mice were procured from the National Laboratory Animal Center (Beijing, China) and maintained in SPF animal laboratory, with the approval of the Animal Research Ethics Committee of Tianjin Medical University Cancer Institute and Hospital. MCF-7 cells transfected with pcDNA 3.1/HAND2-AS1 or pcDNA 3.1 were injected to mice subcutaneously for 28 days to form in vivo models of breast cancer, with tumor volume recorded every 4 days. The tumor samples from killed mice were weighed for further analysis.
4.13. Immunohistochemistry (IHC)
The tumor tissue samples from in vivo study were fixed by 4% paraformaldehyde and embedded in paraffin. After cutting, the sections of 4 μm thick were subjected to IHC using anti-Ki67 (Santa Cruz Biotechnology), through which we evaluated the proliferation marker Ki67 in tumor tissues from the pcDNA 3.1/HAND2-AS1 group with the pcDNA 3.1 group as a control.
4.14. Statistical Analysis
All assays included three biological repeats. Data were processed by Student’s test to compare between two groups, and ANOVA (one-way) was adopted when three or more groups were included in data in GraphPad PRISM 6 (GraphPad, San Diego, CA, USA), with as the cutoff value.
The data used to support the findings of this study are available from the corresponding authors upon request.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
The study was funded by the Key Task Project of Tianjin Health and Family Planning Commission (16KG128), Anticancer Key Technologies R&D Program of Tianjin (12ZCDZSY16200), Natural Science Foundation of Tianjin (18JCYBJC91600), and National Natural Science Foundation of China (81672623).
- C. Woolston, “Breast cancer,” Nature, vol. 527, no. 7578, 2015.
- K. L. Maughan, M. A. Lutterbie, and P. S. Ham, “Treatment of breast cancer,” American Family Physician, vol. 81, no. 11, pp. 1339–1346, 2010.
- L. Yang, N. Xie, J. Huang et al., “SIK1-LNC represses the proliferative, migrative, and invasive abilities of lung cancer cells,” Oncotargets and Therapy, vol. 11, pp. 4197–4206, 2018.
- C. Ye, Z. Shen, B. Wang et al., “A novel long non-coding RNA lnc-GNAT1-1 is low expressed in colorectal cancer and acts as a tumor suppressor through regulating RKIP-NF-κB-Snail circuit,” Journal of Experimental & Clinical Cancer Research, vol. 35, no. 1, p. 187, 2016.
- Z. Li, D. Yu, H. Li, Y. Lv, and S. Li, “Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway,” International Journal of Oncology, vol. 54, no. 3, pp. 1033–1042, 2019.
- F. Ma, X. Liu, S. Zhou et al., “Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop,” Cancer Letters, vol. 450, pp. 63–75, 2019.
- J. Zhou, J. Lin, H. Zhang, F. Zhu, and R. Xie, “LncRNA HAND2-AS1 sponging miR-1275 suppresses colorectal cancer progression by upregulating KLF14,” Biochemical and Biophysical Research Communications, vol. 503, no. 3, pp. 1848–1853, 2018.
- J. R. Yang, M. X. Shi, and Y. Zeng, “LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275,” European Review for Medical and Pharmacological Sciences, vol. 23, no. 5, pp. 2103–2111, 2019.
- F. Miao, J. Chen, M. Shi, Y. Song, Z. Chen, and L. Pang, “LncRNA HAND2-AS1 inhibits non-small cell lung cancer migration, invasion and maintains cell stemness through the interactions with TGF-β1,” Bioscience Reports, vol. 39, no. 1, 2019.
- F. Liu, J. H. Yuan, J. F. Huang et al., “Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a,” Oncogene, vol. 35, no. 41, pp. 5422–5434, 2016.
- X. Yu, J. Zhao, and Y. He, “Long non-coding RNA PVT1 functions as an oncogene in human colon cancer through miR-30d-5p/RUNX2 axis,” Journal of the Balkan Union of Oncology, vol. 23, no. 1, pp. 48–54, 2018.
- J. Long, J. Xiong, Y. Bai et al., “Construction and investigation of a lncRNA-associated ceRNA regulatory network in cholangiocarcinoma,” Frontiers in Oncology, vol. 9, 2019.
- Z. Zhang, W. Qian, S. Wang et al., “Analysis of lncRNA-associated ceRNA network reveals potential lncRNA biomarkers in human colon adenocarcinoma,” Cellular Physiology and Biochemistry, vol. 49, no. 5, pp. 1778–1791, 2018.
- X. Jiang, Y. Zhou, A. J. Sun, and J. L. Xue, “NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1,” Journal of Cellular Physiology, vol. 233, no. 11, pp. 8558–8566, 2018.
- H. B. Hu, Q. Chen, and S. Q. Ding, “LncRNA LINC01116 competes with miR-145 for the regulation of ESR1 expression in breast cancer,” European Review for Medical and Pharmacological Sciences, vol. 22, no. 7, pp. 1987–1993, 2018.
- S. Vienberg, J. Geiger, S. Madsen, and L. T. Dalgaard, “MicroRNAs in metabolism,” Acta Physiologica, vol. 219, no. 2, pp. 346–361, 2017.
- L. Zhou, L. C. Zhao, N. Jiang et al., “MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2,” European Review for Medical and Pharmacological Sciences, vol. 21, no. 1, pp. 87–94, 2017.
- Y. Hu, Z. Tang, B. Jiang, J. Chen, and Z. Fu, “miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1,” Oncology Letters, vol. 13, no. 3, pp. 1753–1760, 2017.
- Y. Wang and X. Cai, “Long noncoding RNA HAND2-AS1 restrains proliferation and metastasis of breast cancer cells through sponging miR-1275 and promoting SOX7,” Cancer Biomarkers, vol. 27, no. 1, pp. 85–94, 2020.
- M. Wei, L. Liu, and Z. Wang, “Long non-coding RNA heart and neural crest derivatives expressed 2-antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple-negative breast cancer,” Oncology Letters, vol. 18, no. 6, pp. 6775–6780, 2019.
- Y. Yan, S. Li, S. Wang et al., “Long noncoding RNA HAND2-AS1 inhibits cancer cell proliferation, migration, and invasion in esophagus squamous cell carcinoma by regulating microRNA-21,” Journal of Cellular Biochemistry, vol. 120, no. 6, pp. 9564–9571, 2019.
- H. Zhang, B. Zhao, X. Wang, F. Zhang, and W. Yu, “LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis,” Life Sciences, vol. 228, pp. 135–144, 2019.
- H. Zhong, J. Yang, B. Zhang et al., “LncRNA GACAT3 predicts poor prognosis and promotes cell proliferation in breast cancer through regulation of miR-497/CCND2,” Cancer Biomarkers, vol. 22, no. 4, pp. 787–797, 2018.
- J. Chen, Y. Lin, Y. Jia, T. Xu, F. Wu, and Y. Jin, “LncRNA HAND2-AS1 exerts anti-oncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA-340-5p,” Journal of Cellular Physiology, vol. 234, no. 12, pp. 23421–23436, 2019.
- D. G. Nowak, H. Cho, T. Herzka et al., “MYC drives Pten/Trp53-deficient proliferation and metastasis due to IL6 secretion and AKT suppression via PHLPP2,” Cancer Discovery, vol. 5, no. 6, pp. 636–651, 2015.
- J. Liu, M. A. Eckert, B. T. Harada et al., “m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer,” Nature Cell Biology, vol. 20, no. 9, pp. 1074–1083, 2018.
- L. Gu, C. Xie, Q. Peng, J. Zhang, J. Li, and Z. Tang, “Arecoline suppresses epithelial cell viability through the Akt/mTOR signaling pathway via upregulation of PHLPP2,” Toxicology, vol. 419, pp. 32–39, 2019.
- X. Yan, W. Li, L. Yang et al., “MiR-135a protects vascular endothelial cells against ventilator-induced lung injury by inhibiting PHLPP2 to activate PI3K/Akt pathway,” Cellular Physiology and Biochemistry, vol. 48, no. 3, pp. 1245–1258, 2018.
- C. Nigro, P. Mirra, I. Prevenzano et al., “miR-214-dependent increase of PHLPP2 levels mediates the impairment of insulin-stimulated Akt activation in mouse aortic endothelial cells exposed to methylglyoxal,” International Journal of Molecular Sciences, vol. 19, no. 2, 2018.
- Y. Liang, C. Zhang, M. H. Ma, and D. Q. Dai, “Identification and prediction of novel non-coding and coding RNA-associated competing endogenous RNA networks in colorectal cancer,” World Journal of Gastroenterology, vol. 24, no. 46, pp. 5259–5270, 2018.
Copyright © 2020 Guolei Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.